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Abstract: Nicotinic acetylcholine receptors (nAChRs) are targets for developing new drugs to treat
severe pain, nicotine addiction, Alzheimer disease, epilepsy, etc. α-Conotoxins are biologically
and chemically diverse. With 12–19 residues and two disulfides, they can be specifically selected
for different nAChRs. Acetylcholine-binding proteins from Aplysia californica (Ac-AChBP) are
homologous to the ligand-binding domains of nAChRs and pharmacologically similar. X-ray
structures of the α-conotoxin in complex with Ac-AChBP in addition to computer modeling have
helped to determine the binding site of the important residues of α-conotoxin and its affinity for
nAChR subtypes. Here, we present the various α-conotoxin residues that are selective for Ac-AChBP
or nAChRs by comparing the structures of α-conotoxins in complex with Ac-AChBP and by modeling
α-conotoxins in complex with nAChRs. The knowledge of these binding sites will assist in the
discovery and design of more potent and selective α-conotoxins as drug leads.
Keywords: α-conotoxins; nAChRs; Ac-AChBP; X-ray structure; model; design
1. Introduction
Nicotinic acetylcholine receptors (nAChRs) are members of ligand-gated ion channels; they
respond to the neurotransmitters acetylcholine and choline. Consequentially, nAChRs are drug
targets for the treatment of severe pain, cognitive decline, epilepsy, and nicotine addiction [1–5].
α-Conotoxins, which come from sea Conus snails, are important tool for studying nAChRs. They are
also used as pharmacological probes and as potential therapeutic agents for the treatment of severe
pain [6–12]. α-Conotoxins are diverse and target a variety of nAChR subtypes. Examples include:
α-conotoxins GI, SI, and SIA selectively block Torpedo nAChR [13–15]; α-conotoxins MII and PeIA block
rα3β2- and rα6-containing nAChRs [16–18]; Vc1.1 and RgIA target the rα9α10 (rat α9α10) nAChR
subtypes [19–22]; ImI targets hα7 (human α7) and hα3β2 nAChRs [23]; and TxIA (A10L) has an affinity
for the rα3β2 and h(r)α7 (human and rat α7) subtype receptors [24].
The residues of α-conotoxins are important for determining nAChR subtypes selectivity and
potency. For instance, the A10L mutation in α-conotoxin PnIA causes a switch in selectivity from the
rα3β2 to the rα7 nAChR [25,26]. Arg-5 in α-conotoxin TxIA is an efficient blocker of rα3β2 nAChR [24];
Arg-7 and Trp-10 in α-conotoxins ImI and ImII were shown to have high affinity for hα7 nAChR [23,27];
Arg-7 in α-conotoxins RgIA and Vc1.1 affected their binding to rα9α10 nAChR [28–31]; His-5 in several
α-conotoxins (GIC, PeIA, OmIA) act as key residues that bind with different neuronal nAChRs [32–35];
and the positively charged residues Lys and Arg in the C-terminal region increase 3/5 α-conotoxins GI,
SI, and SIA, targeting the Torpedo nAChR [13,15]. α-Conotoxins consist of two loops: loop 1 residues
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are more similar and conserved, loop 2 residues are more variable and not conserved. In general, the
loop 2 residues are required for selectivity, and the loop 1 residues are crucial for binding (irrespective
of the residues, which are most selective) [19]. The residues of α-conotoxin replacements leading to
increased potency and selectivity to the receptors are shown in Table 1.
Table 1. The residues of α-conotoxin replacements leading to increased potency and selectivity to
the receptors.
α-Conotoxins Potent Variant Targed AChBPsor nAChRs Increasing Affinity
PnIA
PnIA (A10L) h(r)α7 ~10-fold [26,36]
PnIA (L5R A10L) rα3β2 20-fold [24]
PnIA (A10L D14K) Ls-AChBP 10-fold [36]
PnIA (L5R, A10L, D14R) hα7 21-fold [37]
PnIA (L5H) Ac-AChBP 18-fold [37]
TxIA
TxIA (A10L) rα3β2 ~1.5-fold [24]
TxIA (A10L) rα7 10-fold [24]
SIA
SIA (D12S) Torpedo 27-fold for high affinity site [15]
SIA (D12K) Torpedo 35-fold for high affinity site [15]
GI
GI (S12R) Torpedo 3-fold for high affinity site [15]
GI (S12K) Torpedo 5-fold for high affinity site [15]
SI SI (S12R) Torpedo 4-fold for high affinity site [15]
GID GID (γ4E) rα4β2 1-fold [38,39]
PeIA
PeIA (H5N) rα6/α3β2β3 6-fold [18]
PeIA (A7V) rα6/α3β2β3 2-fold [18]
PeIA (S9R) rα6/α3β2β3 7-fold [18]
PeIA (A7V, S9H, V10A, N11R, E14A) rα6/α3β2β3 ~8-fold [18]
PeIA (S9R) rα3β2 4-fold [18]
PeIA (V10L) rα3β2 5-fold [18]
Vc1.1
Vc1.1 (N9G, A, I, L), (S4R) rα9α10 ~8-fold [19]
Vc1.1 (N9G, A, I, L), (S4R), (S4K, N9A) hα9rα10 ~25-fold [19]
Vc1.1 (N9A, I, L) rα3β2 ~50, 20, 2-fold respectively [19]
Vc1.1 (N9W) hα9rα10 ~30-fold [31]
MII
RDP-MII rα6β2 13-fold [40]
RDP-MII (E11R) rα6β2 13-fold [40]
Since α-conotoxins and variants have different potency and selectivity, it is important to
understand the characteristics at the molecular level to facilitate discovery and design of potent
α-conotoxin analogs [3,41].
Acetylcholine-binding protein from Aplysia californica (Ac-AChBP) is a homologous
ligand-binding domain of nAChRs [1,42–44]. X-ray structures of α-conotoxins in complex with
Ac-AChBP generated new insights into the spatial structure of α-conotoxin interaction with particular
nAChRs. The information allowed us to determine the important amino acid residues for binding
and selectivity. Currently, five important structures of α-conotoxins in complex with Ac-AChBP
have been solved. They are the PnIA variant (PDB: 2BR8) [36], ImI (PDB: 2C9T, 2BYP) [45,46],
the TxIA variant (PDB: 2UZ6) [24], BuIA (PDB: 4EZ1), and GIC (PDB: 5CO5) [47]. As shown in Figure 1,
the five α-conotoxins in complex with Ac-AChBP structures show a similar spatial structure and nearby
binding loop C of the Ac-AChBP; however, the α-conotoxin sequences differ, so they have various
binding patterns. For instance, TxIA (A10L) shows a 20◦ backbone tilt relative to other conotoxin
complexes [24].










Figure  1. Different  crystal  structures  of  α‐conotoxins  in  complex with Ac‐AChBP.  (A)  Sequence 
alignment  of  α‐conotoxins GIC,  PnIA  (A10L, D14K),  TxIA  (A10L),  BuIA,  and  ImI;  red  residues 
indicate  the  nonconserved  residues  selective  for  the  acetylcholine‐binding  protein  from  Aplysia 
californica (Ac‐AChBP) principal side; blue residues indicate the nonconserved residues selective for 
the Ac‐AChBP  complementary  side  [24,45,47,48];  (B)  the  crystal  structure  of  α‐conotoxin GIC  in 
complex with Ac‐AChBP  (PDB: 5CO5)  [47];  (C) α‐conotoxin PnIA  (A10L, D14K)  (PDB: 2BR8) [36]; 
(D)  α‐conotoxin TxIA  (A10L)  (PDB:  2UZ6)  [24];  (E)  α‐conotoxin BuIA  [48]  (PDB:  4EZ1);  and  (F) 
α‐conotoxin ImI in complex with Ac‐AChBP (PDB: 2C9T) [45]. 
From the crystal structure of five α‐conotoxins in complex with Ac‐AChBP, it was found that 
the  five α‐conotoxins bound  to a similar position of  the nearby  loop C of  the Ac‐AChBP, and  the 
binding  pattern  is  also  similar.  The  structures  of  α‐conotoxins  are  largely  determined  by  the 
conserved disulfide  connectivity between CysI–CysIII and CysII–CysIV  [47,49]. The mutations of 
α‐conotoxin, which were observed in the Ala substitutions (no change of the disulfide connectivity), 
showed  no major  changes  in  secondary  structure  (except  Pro  residue)  [19,38];  the  α‐conotoxin 
mutants  have  a  well‐defined  helix  that  is  similar  to  native  conotoxins.  From  the  structure  of 
α‐conotoxins in complex with Ac‐AChBP, and as shown by many experiments, it is assumed that the 
α‐conotoxin mutants were binding at a similar site of the receptor and displaying binding patterns 
Figure 1. Different crystal structures of α-conotoxins in complex with Ac-AChBP.
(A) Sequence alignment of α-conotoxins GIC, PnIA (A10L, D14K), TxIA (A10L), BuIA, and ImI;
red residues indicate the nonconserved residues selective for the acetylcholine-binding protein from
Aplysia californica (Ac-AChBP) principal side; blue residues indicate the nonconserved residues
selective for the Ac-AChBP complementary side [24,45,47,48]; (B) the crystal structure of
α-conotoxin GIC in complex with Ac-AChBP (PDB: 5CO5) [47]; (C) α-conotoxin PnIA (A10L, D14K)
(PDB: 2BR8) [36]; (D) α-conotoxin TxIA (A10L) (PDB: 2UZ6) [24]; (E) α-conotoxin BuIA [48]
(PDB: 4EZ1); and (F) α-conotoxin ImI in complex with Ac-AChBP (PDB: 2C9T) [45].
From the crystal structure of five α-conotoxins in complex with Ac-AChBP, it was found that the
five α-conotoxins bound to a similar position of the nearby loop C of the Ac-AChBP, and the binding
pattern is also similar. The structures of α-conotoxins are largely determined by the conserved disulfide
connectivity between CysI–CysIII and CysII–CysIV [47,49]. The mutations of α-conotoxin, which were
observed in the Ala substitutions (no change of the disulfide connectivity), showed no major changes
in secondary structure (except Pro residue) [19,38]; the α-conotoxin mutants have a well-defined helix
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that is similar to native conotoxins. From the structure of α-conotoxins in complex with Ac-AChBP,
and as shown by many experiments, it is assumed that the α-conotoxin mutants were binding at
a similar site of the receptor and displaying binding patterns similar to native conotoxins [47,49].
Most conotoxins share a common folding structure that is not expected to change upon binding,
therefore “rigid” docking can be performed to determine the residues responsible for α-conotoxin’s
binding and selectivity for nAChRs [41,50–52].
The structure of conotoxins bound by nAChRs is similar to the crystal structure of the conotoxins
in complex with Ac-AChBP [36]. For instance, the backbone tilt of conotoxin PnIA (A10L D14K) bound
by hα7 nAChR is similar to the crystal structure of PnIA (A10L D14K) in complex with Ac-AChBP
(PDB: 2BR8) [36]. This is favorable for using computer models to design and discover new potent
α-conotoxins [2,3,51–53].
Here, we review the data of the co-crystal structure of α-conotoxins in complex with Ac-AChBP
and some of the computer models of α-conotoxins selective for nAChRs, which will help to discover
and design α-conotoxin analogs with higher selectivity for nAChRs.
2. α-Conotoxin Residue-Binding and Selectivity for Ac-AChBP
2.1. Asn-11, Asn-12 Residues of PnIA (A10L D14K), TxIA (A10L), and GIC Are the Key Residues for Binding
to Ac-AChBP
Asn-11 and Asn-12 are conserved in many α-conotoxins (shown in Figure 1A) [2]. From the crystal
structure of α-conotoxins in complex with Ac-AChBP, it was found that Asn-11 and Asn-12 mainly
bind to loop C of Ac-AChBP. A comparison of the Asn-11 and Asn-12 residues of the α-conotoxins
in the crystal structure is shown in Figure 2. In Figure 2A, Asn-11 and Asn-12 of PnIA (A10L D14K),
TxIA (A10L) and GIC form a hydrogen bond with the principal side (“+”-side, indicated in green,
the residue-binding ligand is near loop C) [36] residues, Glu-191 and Tyr-91, and with the
complementary side (“−“-side, indicated in blue, the residue-binding ligand is near loop E) [36,51]
residues Arg-77. Mutating the residues of Asn-11 and Asn-12 to Ala resulted in the loss of affinity for
Ac-AChBP [47]. Arg-11 of ImI is also a key residue for binding to Ac-AChBP. As shown in Figure 2B,
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5CO5)  [47]  positions  are  similar  and  form  hydrogen  bonds with  the  principal  side Glu‐191  and 
Tyr‐91 and  the complementary side Arg‐77 of Ac‐AChBP;  (B)  the position of Arg‐11  in  ImI  (PDB: 
2C9T)  [45]  is  similar  to Asn‐11 of GIC, which also  contacts  the Ac‐AChBP principal  side  residue 
Glu‐191. 
The  function of  the Asn‐11  and Asn‐12  residues was  also demonstrated by  the  α‐conotoxin 
PnIA  (A10L)  truncation  assay  [54]. PnIA  (A10L)  loop  2  truncation  indicated  that  removal of  the 
residues (Pro‐13, Asp‐14, Tyr‐15), after Asn‐12 did not much affect PnIA (A10L) binding to rα7, but 
Figure 2. Comparison of different α-conotoxins Asn-11 and Asn-12 bound by Ac-AChBP.
(A) Asn-11 and Asn-12 of PnIA (A10L D14K) (PDB: 2BR8) [36], TxIA (A10L) (PDB: 2UZ6) [24], and GIC
(PDB: 5CO5) [47] positions are similar and form hydrogen bonds with the principal side Glu-191
and Tyr-91 and the complementary side Arg-77 of Ac-AChBP; (B) the position of Arg-11 in ImI (PDB:
2C9T) [45] is similar to Asn-11 of GIC, which also contacts the Ac-AChBP principal side residue Glu-191.
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The function of the Asn-11 and Asn-12 residues was also demonstrated by the α-conotoxin PnIA
(A10L) truncation assay [54]. PnIA (A10L) loop 2 truncation indicated that removal of the residues
(Pro-13, Asp-14, Tyr-15), after Asn-12 did not much affect PnIA (A10L) binding to rα7, but when
truncated to Asn-12, the PnIA (A10L) lost the activity to rα7 and acetylcholine-binding protein from
Lymnaea stagnalis (Ls-AChBP). The sequence length of α-conotoxin ImI is similar to that of PnIA
(A10L) as the removal of the residues (Asn-12, Pro-13, Asp-14, Tyr-15), but it has higher affinity to rα7
nAChR. The reason is that the residues Asp-5 and Arg-11 of ImI and the residues Asn-11 and Asn-12
of PnIA (A10L) have similar positions, respectively. Within the binding pocket of rα7, they can form
hydrogen bonds with rα7 residues Glu-191, Tyr-193, and Tyr-91. So, ImI activity is actually similar to
the full-length PnIA (A10L) [54].
2.2. His-5 of GIC, Arg-5 of TxIA (A10L), and Arg-7 of ImI Are the Important Residues Responsible for
α-Conotoxin’s Selectivity for the Ac-AChBP Principal Side
His-5 in α-conotoxin GIC acts as a key residue for contacting with the hα3β2 nAChRs [47];
Arg-5 acts as a key residue, binding with rα3β2 nAChR [24]; and Arg-7 is a key residue of α-conotoxin
ImI for its high affinity to hα7 nAChR [45]. Comparison of the crystal structures is shown in Figure 3.
His-5 of GIC, Arg-5 of TxIA (A10L), and Arg-7 of ImI reside in similar positions. His-5 of GIC contacts
Tyr-91 and Tyr-186; Arg-5 of TxIA (A10L) protrudes into the principal binding site and contacts Asp-195
and Tyr-186; and Arg-7 of ImI is also located in a similar position and contacts Tyr-91, Trp-145, IIe-194,
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the  complementary  side  of Ac‐AChBP. Comparison  of  Ser‐4  in  the  crystal  structure  of different 
α‐conotoxins is shown in Figure 4. In Figure 4A, it is shown that Ser‐4 of GIC and PnIA (A10L D14K) 
are key residues for binding to the Ac‐AChBP complementary side residues Asp‐162, Ser‐164, and 





Figure 3. Comparison of His-5 of GIC (PDB: 5CO5) [47], Arg-5 of TxIA (A10L) (PDB: 2UZ6) [24],
and Arg-7 of ImI bound by the Ac-AChBP principal side. His-5 of GIC contacts Tyr-91 and Tyr-186 of
Ac-AChBP. Arg-5 of TxIA (A10L) protrudes into the principal binding site and contacts Asp-195 and
Tyr-186. Arg-7 of ImI (PDB: 2C9T) [45] contacts Tyr-91, Tyr-186, and IIe-194 of Ac-AChBP.
2.3. Ser-4 of GIC, PnIA (A10L D14K), and ImI Are Key Residues for Interaction with the Ac-AChBP
Complementary Side
Ser-4 is highly conserved in many α-conotoxins (shown in Figure 1A), which usually binds
to the complementary side of Ac-AChBP. Comparison of Ser-4 in the crystal structure of different
α-conotoxins is shown in Figure 4. In Figure 4A, it is shown that Ser-4 of GIC and PnIA
(A10L D14K) are key residues for binding to the Ac-AChBP complementary side residues Asp-162,
Ser-164, and Ser-165. Ser-4 of α-conotoxin TxIA (A10L), with a 20◦ backbone tilt rotation, makes only
weak contact with Ser-165 of the Ac-AChBP complementary side [24,36,47].





side.  (A) Ser‐4 of GIC  (PDB: 5CO5)  [47] makes hydrogen bonds with Asp‐162, Ser‐164, or Ser‐165. 
Ser‐4 of PnIA (A10L D14K) (PDB: 2BR8) [36] is located in a position similar to that of GIC and forms 
hydrogen bonds with the three residues. Ser‐4 of α‐conotoxin TxIA (A10L) (PDB: 2UZ6) [24], with a 
20°  rotating backbone  tilt, makes only weak  contact with  the Ac‐AChBP  complementary  residue 
Ser‐165; (B) Ser‐4 of ImI  (PDB: 2C9T)  [45]  is  located on  the right side of Ser‐4 of GIC and contacts 





for h(r)α7 nAChRs. Gln‐13  of GIC  is  an  important  residue  for  affinity  for hα3β2. The  co‐crystal 










4EZ1) reside  in positions similar  to Leu‐10 of PnIA  (A10L D14K), but Val‐10 of BuIA  forms  fewer 
contacts due  to  the shorter  length of  its side‐chain compared  to Leu‐10 and results  in a decreased 
affinity to Ac‐AChBP. 
Figure 4. Comparison of different α-conotoxins with Ser-4 bound by the Ac-AChBP complementary
side. (A) Ser-4 of GIC (PDB: 5CO5) [47] makes hydrogen bonds with Asp-162, Ser-164, or Ser-165.
Ser-4 of PnIA (A10L D14K) (PDB: 2BR8) [36] is located in a position similar to that of GIC and forms
hydrogen bonds with the three residues. Ser-4 of α-conotoxin TxIA (A10L) (PDB: 2UZ6) [24], with a 20◦
rotating backbone tilt, makes only weak contact with the Ac-AChBP complementary residue Ser-165;
(B) Ser-4 of ImI (PDB: 2C9T) [45] is located on the right side of Ser-4 of GIC and contacts Asp-162;
Ser-4 of BulA [48] (PDB: 4EZ1) is located on the left side of Ser-4 of GIC and forms a hydrogen bond
with Ser-165.
Figure 4B shows Ser-4 of ImI located on the right side of Ser-4 of GIC and forms a hydrogen bond
with Asp-162. Ser-4 of BulA is located on the left side of Ser-4 of GIC and forms a hydrogen bond with
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2.4. Leu‐10 of PnIA (A10L D14K) and TxIA (A10L), Gln‐13 of GI , and Trp‐10  f ImI Are Important 
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for h(r)α7 nAChRs. Gln‐13  of GIC  is  an  important  residue  for  affinity  for hα3β2. The  co‐crystal 
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of Arg-7 , Val-106, Thr-108, Ser-112, and Met-114. (A) Leu-10 of PnIA (A10L D14K), Gln-13
of GIC (PDB: 5CO5) [47], and W10 of ImI (PDB: 2C9T) [45] reside in the pocket. Gln-13 of GIC f rms a
hydrogen bond with Ser-112 of Ac-AChBP [47], but W10 of ImI makes a hydrogen bond with Arg-77 of
c-AChBP [45]; (B) Leu-10 of TxIA (A10L) (PDB: 2UZ6) [24] and Val-10 of BuIA [48] (PDB: 4EZ1) reside
in positions similar to Leu-10 of PnIA (A10L D14K), but Val-10 of BuIA forms fewer contact ue to the
shorter length f its side-chain compared to Leu-10 and results in a decreased affinity to Ac-AChBP.
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2.4. Leu-10 of PnIA (A10L D14K) and TxIA (A10L), Gln-13 of GIC, and Trp-10 of ImI Are Important Residues
Responsible for α-Conotoxin’s Selectivity for the Ac-AChBP Complementary Side
Leu-10 in α-conotoxin PnIA (A10L D14K) selects for h(r)α7 nAChRs. Trp-10 of ImI has affinity
for h(r)α7 nAChRs. Gln-13 of GIC is an important residue for affinity for hα3β2. The co-crystal
comparison is shown in Figure 5. In Figure 5A, Leu-10 of PnIA (A10L D14K), Tyr-10 of ImI,
and Gln-13 of GIC reside in a pocket consisting of Arg-77, Val-106, Thr-108, Ser-112, and Met-114 of
the complementary Ac-AChBP. Leu-10 of PnIA (A10L D14K) and Gln-13 of GIC serve as anchors and
enhance the affinity for the Ac-AChBP complementary side [36,45,47].
Tyr-10 of ImI is also located in the pocket consisting of Arg-77, Val-106, Thr-108, Ser-112, and
Met-114. Importantly, the substitution of Val-106 by Arg-106 in Ls-AChBP induces a steric clash
with Tyr-10 of ImI, hence the ImI decreases 14,000-fold binding affinity to Ls-AChBP compared with
Ac-AChBP [3,45].
Figure 5B shows that Leu-10 of TxIA (A10L) and Val-10 of BuIA [49] reside in positions similar to
Leu-10 of PnIA (A10L D14K) and make contact with Arg-77, Val-106, Thr-108, Ser-112, and Met-114
of the Ac-AChBP complementary side, but Val-10 of BuIA forms fewer contacts due to the shorter
length of its side-chain compared to Leu-10, resulting in a lower affinity to Ac-AChBP than PnIA
(A10L D14K) [24].
3. α-Conotoxin Residues Selective for nAChRs
From the α-conotoxins complex with Ac-AChBP structure, and as shown in many experiments,
it is assumed that α-conotoxin binding sites of nAChRs are similar to the binding sites of
Ac-AChBP [1,36,49]. Sequence alignment of Ac-AChBP, Ls-AChBP, h(r)α3, h(r)α4, h(r)α6, h(r)α7,
and h(r)α10 residues forming binding sites on the principal side are shown in Figure 6A. The residues
forming binding sites on the complementary side are shown in Figure 6B. In Figure 6, it is shown
that different nAChRs have different residues in the binding site, which could affect the conotoxin’s
affinity. For example, the Ile-57 (number 59 in that study [31]) of hα9 was replaced by Thr-57 in rα9
(Figure 6B) result in α-conotoxin Vc1.1 increased affinity 10 folds for the rat receptor [31]. Modelling
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Only  the Gln13‐Ala  substitution had  the  least  influence on GIC  activity  in hα3β2 or Ac‐AChBP. 
From the GIC/hα3β2 complex model, it was found that Gln‐13‐Ala substitution had little effect, and 
it fit well with the receptor. Gln‐13 or Ala‐13 of GIC also fit well with the hα3β2 receptor, but Gln‐13 
Figure 6. Primary sequence alignment of Ac-AChBP, acetylcholine-binding protein from
Lymnaea stagnalis (Ls-AChBP), h(r)α3, h(r)α4, h(r)α6, h(r)α7, h(r)α10, h(r) β2, h(r) β4, and h(r) α9
residues forming the binding sites to accommodate α-conotoxins. (A) The residues forming the binding
sites on the principal side; (B) the residues forming the binding sites on the complementary side.
Mar. Drugs 2016, 14, 173 8 of 14
3.1. Residues of α-Conotoxin GIC Selective for hα3β2
As we have mentioned before, Gln-13 and His-5 of α-conotoxin GIC have high affinity for hα3β2.
By docking α-conotoxin GIC to hα3β2, it was found that the GIC/hα3β2 complex was similar to
the GIC/Ac-AChBP crystal structure. Mutation of His-5, Asn-11, and Asn-12 to Ala in α-conotoxin
GIC (Figure 7A) caused a loss of affinity for Ac-AChBP. The mutations also lost affinity for hα3β2.
Only the Gln13-Ala substitution had the least influence on GIC activity in hα3β2 or Ac-AChBP.
From the GIC/hα3β2 complex model, it was found that Gln-13-Ala substitution had little effect, and it
fit well with the receptor. Gln-13 or Ala-13 of GIC also fit well with the hα3β2 receptor, but Gln-13 of
GIC caused a steric clash with Arg-108 in the hβ4 complementary binding side (Figure 6B) and lost
affinity to hα3β4 [35,47].
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Figure 7. Residues of different α-conotoxins affect selectivity for nicotinic acetylcholine receptors
(nAChRs). (A) The residues of mutant GIC ( ), ( 11A), (N12A), and (Q13A) affect its selectivity
for hα3β2; (B) the residues of muta t PnIA (L5R, A10L, D14R) affect its selectivity for hα7;
(C) the residues of mutant SIA (D12K) affect its selectivity for Torpedo nAChR; (D) the residues of
mutant MII (G1RDP) and (E11R) affect its selectivity for rα6β2 or rα3β2 nAChR; (E) the residues of
mutant Vc1.1 (S4K, R) and (N9A, I, L) affect its selectivity for h(r)α9rα10 nAChRs.
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3.2. Residues of α-Conotoxin PnIA Selective for hα7
As previously mentioned, A10L in PnIA (A10L) has higher affinity to Ac-AChBP and hα7
nAChR [36]. The docking study found that Leu-10 of PnIA (A10L) interacts with the hα7 nAChR
hydrophobic pocket, which is composed of the residues Leu-106, Asn-108, His-112, and Gln-114 in the
complementary side (Figure 6B). Consequently, A10L mutation could extend the hydrophobic regions
and increase the binding to the hydrophobic pocket of the receptor [3,36,37].
PnIA mutations (Figure 7B) PnIA (L5R, A10L, D14R) display a 10-fold higher affinity for the
hα7 nAChR compared to that of PnIA (A10L) [37]. The reason could be explained by Leu-5 of the
PnIA being in the vicinity of hα7 residues Asp-195, Tyr-193 (loop C), and Tyr-91. In the L5R mutation,
the Arg-5 of the PnIA could form hydrogen bonds with those residues of hα7. Asp-14 of the PnIA is in
the vicinity of hα7 residues His-114, Asn-110, and Lys75. The D14K mutation in PnIA (A10L) does
not have much effect on its affinity to hα7 [36], but PnIA (L5R, A10L, D14R) shows high affinity to
hα7; this may be due to the fact that the Arg-14 forms hydrogen bonds with Asn-110 residues of hα7
nAChRs [37].
3.3. Residues of α-Conotoxins SIA Selective for Torpedo nAChR
The PnIA (A10L D14K) mutation shows higher affinity for Ls-AChBP. Modeling studies found
that the Lys-14 residue of PnIA (A10L D14K) forms a salt bridge with Glu-110 of the Ls-AChBP
complementary site [36]. Kasheverov et al. found that adding positively charged residues
(Lys or Arg) in the C-terminal region of α-conotoxins increased binding affinity to some nAChRs [15].
For example, the α-conotoxin SIA (D12K) mutation (Figure 7C) showed higher affinity of Torpedo
nAChRs. The reason could be similar to the D14K mutation in PnIA (A10L) which gained a higher
affinity for Ls-AChBP [15]. Its Lys-12 in SIA (D12K) formed a salt bridge with Glu-57 of the Torpedo
nAChRγ subunit and increased binding affinity to it [15].
3.4. Residues of α-Conotoxins MII Selective for rα6β2 nAChRs
Gotti et al. discovered that the α-conotoxin MII selectively blocked rα6β2 nAChRs [40], Gly-1 of
MII was mutated to three amino acids RDP (arginine (R), aspartic acid (D), and proline (P)) (Figure 7D),
and the N-terminal amino acid tail motif RDP of MII increased affinity for the rα6β2 receptor by
13-fold. Modeling studies found that Arg-1 of the RDP motif makes hydrogen bonds with Asp-166
and Asp-167 of the β2 subunit [40].
Mutation of the conotoxin MII to MII (E11R) with a highly positively charged residue Arg-11
also favors local contact with the negatively charged area (Glu-19, Asp-148, Glu-151, Glu-191),
and Arg-11 makes a hydrogen bond with Glu-151 (Figure 8A). So the MII (E11R) mutation also
has affinity to rα6β2. Glu-19 and Glu-151 in the α6 chain are replaced by Ala-19 and Lys-151 in the
α3 receptor, thus making the α3 receptor binding site more positively charged and not favorable
for Arg-11 of MII(E11R) to be bound by the receptor. Then, the MII (E11R) lost affinity for rα3β2
(Figure 8B). So MII (E11R) could be selective for rα6β2 vs. rα3β2 [40].
3.5. Residues of α-Conotoxins Vc1.1 Selective for α9α10 nAChR
Vc1.1 is a conotoxin from Conus Victoriae (Figure 7E). Mutations of Vc1.1 residues 5–7 and 11–15
to Ala, Lys, or Asp led to a significant decrease of functional activity at the α9α10 nAChR. The reason
is that all these mutations can cause a disruption in the native structure that result in all the peptides
unable to bind to the receptor, or alternatively affecting the specific amino acid interactions [19].
In contrast, substitutions at two other positions, Ser-4 and Asn-9, could improve the functional
activity of Vc1.1 at the α9α10 nAChR. Replacement of Ser-4 by a positive residue (Arg or Lys), is more
favorable for the potency at the rα9α10 and hα9rα10 nAChRs, but not for other receptors [19]. Vc1.1
mainly binds to α9α10 nAChR at the α10α9 pocket (α10 is principle site (+), and α9 is complementary
site (−)). The receptor residues involved in interactions with Ser-4 of Vc1.1 are Asp-169, Asp-166,
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and Thr-32 of α9(−) [31]. Replacement of Ser-4 by Arg or Lys in Vc1.1, may favor the positive residue
binding to those three residues, so increases potency at the α9α10 nAChR.
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Figure 8. Structure basis for the selectivity of MII (E11R) with rα6β2 vs. rα3β2 n ChRs.
(A) The pocket in rα6 is able to accommodate Arg-11 of MII (E11R), and Arg-11 forms a hydrogen bond
with Glu-151 in the α6β2/MII (E11R) model; (B) Lys-151 in the pocket of rα3 is unfavorable for Arg-11
of MII (E11R) binding and then lost affinity to rα3β2 compared wit the rα6β2 nAChRs.
The receptor residues involved in interactions with Asn-9 of Vc1.1 are Gln-34, Arg-57, Thr-59,
Thr-117 of rα9(−).The Th -59 of rα9(−) is r placed by Ile-59 in hα9(−) (the numb r in that study).
Asn-9, when eplaced with a hydrophobi residue (Ala, Ile, Leu), will form more hydrophobic regions,
so affinity to the receptors increased and resulted in more favo able binding potency a the rα9α10
a d hα9rα10 nAC Rs [19].
From hose findings above, it could be suggested that the molecular structure combined with
technology such as scanning mutagenesis, e e trophysiology, etc. [18,19], not only helped us find the
residues of α-conotoxins for various nAChR subtype selectivity, but also helped us design α-conotoxin
analogs of higher potency and selectivity for drug application [41,53–55].
For example, the α-conotoxin Vc1.1 potent variants such as N9A, N9I, N9L and S4R,
which are highly selective for rα9α10, were first discovered by scanning mutagenesis by Craik et al. [19].
Using different computational strategies for modeling α-conotoxin Vc1.1 binding to nAChRs further
determined key residues and binding sites that helped with the design of the new selective analog
Vc1.1 (N9W) [31]. It also helps in the design of stable disulfide-deleted mutant of cyclic α-conotoxin
Vc1.1 (C2H C8F) for oral drug application to treatment of neuropathic pain [56,57].
4. Conclusions
The diversity of α-conotoxins makes them not only excellent pharmacological probes for
the dissection of structural features and functioning of nAChRs but also provides drug leads;
some α-conotoxins are currently undergoing preclinical evaluation for the treatment of chronic and
neuropathic pain. X-ray structures of α-conotoxins in complex with Ac-AChBP provide high-resolution
information of these amino acid interactions and binding patterns. Based on co-crystal structures,
computer models further revealed α-conotoxin residue selectivity for different nAChR subtypes and
helped with the design of potent analogs. So, many potent α-conotoxins have been discovered by
using the molecular structure of α-conotoxins selective for nAChRs, and here we only list some
representatives. Currently, the optimization of drugs usually depends on animal models, but the
drugs intended for human use could be misleading, as large activity differences can arise between
binding site residues displaying some differences. A structural base provides insight to the important
Mar. Drugs 2016, 14, 173 11 of 14
residues for binding to receptors and aids in the design of α-conotoxin analogs that are more potent
for accurate treatment.
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